-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25

Benzinga·08/12/2026 17:39:46
Listen to the news
Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.